Amicus Therapeutics, Inc. (NASDAQ: FOLD) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target raised by analysts at JPMorgan Chase & Co. from $16.00 to $17.00. They now have an "overweight" rating on the stock.
Amicus Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target raised by analysts at Guggenheim from $13.00 to $15.00. They now have a "buy" rating on the stock.
Amicus' Q3 Earnings & Revenues Beat Estimates, '24 View Updated [Yahoo! Finance]